Skip to main content

Market Overview

AC Immune Provides Update On Alzheimer's Disease Vaccine Candidate

AC Immune Provides Update On Alzheimer's Disease Vaccine Candidate
  • AC Immune SA (NASDAQ: ACIU) and its partner Janssen Pharmaceuticals Inc have expanded the ongoing Phase 1b/2a trial evaluating anti-phosphorylated-Tau (pTau) vaccine candidate ACI-35.030 for the treatment of Alzheimer's disease (AD).
  • The trial expansion specifically includes vaccination of additional AD patients at the second-highest dose.
  • In parallel, the trial continues to evaluate patients in the highest dose cohort, for which the first interim results will be available by the end of this year.
  • Interim Phase 1b/2a trial results from the low and second-highest dose groups showed vaccination generated a potent antigen-specific antibody response against pTau in 100% of older patients with early AD with no clinically relevant safety concerns observed to date.
  • In addition to ACI-35.030, AC Immune and Janssen Pharmaceuticals are evaluating an exploratory alternative pTau vaccine candidate, JACI-35.054, in the current Phase 1b/2a trial.
  • Price Action: ACIU shares are up 2.56% at $6.37 on the last check Monday.

Related Articles (JNJ + ACIU)

View Comments and Join the Discussion!

Posted-In: Alzheimer's diseaseBiotech News Health Care Contracts Small Cap FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at